Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth

Biochemical and Biophysical Research Communications

Volumn 368, Issue 3, 2008, Pages 793-800

  Törnkvist, Maria ^a   Natalishvili, Natalia ^a   Xie, Yuntao ^a,b   Girnita, Ada ^a   D'Arcy, Pádraig ^a   Brodin, Bertha ^a   Axelson, Magnus ^c   Girnita, Leonard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Growth; IGF 1 receptor; SS18 SSX; Synovial sarcoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYCLIN D1; DNA; MESSENGER RNA; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; FUSION GENE; GENETIC LINKAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SS18 SSX FUSION GENE; SYNOVIAL SARCOMA;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ONCOGENE PROTEINS, FUSION; RECEPTOR, IGF TYPE 1; SARCOMA, SYNOVIAL; SIGNAL TRANSDUCTION;

EID: 39749166236     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.01.162     Document Type: Article

References (33)

1. Clark J., Rocques P.J., Crew A.J., Gill S., Shipley J., Chan A.M., Gusterson B.A., and Cooper C.S. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 7 (1994) 502-508
2. de Leeuw B., Balemans M., Olde Weghuis D., and Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. Hum. Mol. Genet. 4 (1995) 1097-1099
3. Skytting B., Nilsson G., Brodin B., Xie Y., Lundeberg J., Uhlen M., and Larsson O. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J. Natl. Cancer Inst. 91 (1999) 974-975
4. Nilsson G., Skytting B., Xie Y., Brodin B., Perfekt R., Mandahl N., Lundeberg J., Uhlen M., and Larsson O. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res. 59 (1999) 3180-3184
5. Inagaki H., Nagasaka T., Otsuka T., Sugiura E., Nakashima N., and Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod. Pathol. 13 (2000) 482-488
6. Ladanyi M., Antonescu C.R., Leung D.H., Woodruff J.M., Kawai A., Healey J.H., Brennan M.F., Bridge J.A., Neff J.R., Barr F.G., Goldsmith J.D., Brooks J.S., Goldblum J.R., Ali S.Z., Shipley J., Cooper C.S., Fisher C., Skytting B., and Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 62 (2002) 135-140
7. Xie Y., Skytting B., Nilsson G., Gasbarri A., Haslam K., Bartolazzi A., Brodin B., Mandahl N., and Larsson O. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res. 62 (2002) 3861-3867
8. Xie Y., Skytting B., Nilsson G., Grimer R.J., Mangham C.D., Fisher C., Shipley J., Bjerkehagen B., Myklebost O., and Larsson O. The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. Oncogene 21 (2002) 5791-5796
9. Quelle D.E., Ashmun R.A., Shurtleff S.A., Kato J.Y., Bar-Sagi D., Roussel M.F., and Sherr C.J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7 (1993) 1559-1571
10. Xie Y., Skytting B., Nilsson G., Brodin B., and Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 59 (1999) 3588-3591
11. Burrow S., Andrulis I.L., Pollak M., and Bell R.S. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol. 69 (1998) 21-27
12. Ulfarsson E., Karstrom A., Yin S., Girnita A., Vasilcanu D., Thoren M., Kratz G., Hillman J., Axelson M., Larsson O., and Girnita L. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin. Cancer Res. 11 (2005) 4674-4680
13. Girnita L., Girnita A., Brodin B., Xie Y., Nilsson G., Dricu A., Lundeberg J., Wejde J., Bartolazzi A., Wiman K.G., and Larsson O. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 60 (2000) 5278-5283
14. Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 92 (2000) 1472-1489
15. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth?. Cancer Res. 55 (1995) 249-252
16. Girnita L., Girnita A., and Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 100 (2003) 8247-8252
17. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A., Lefkowitz R.J., and Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J. Biol. Chem. 280 (2005) 24412-24419
18. Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Vasilcanu D., Girnita A., Lefkowitz R.J., and Larsson O. Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J. Biol. Chem. 282 (2007) 11329-11338
19. Adams T.E., Epa V.C., Garrett T.P., and Ward C.W. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol. Life Sci. 57 (2000) 1050-1093
20. All-Ericsson C., Girnita L., Seregard S., Bartolazzi A., Jager M.J., and Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest. Ophthalmol. Vis. Sci. 43 (2002) 1-8
21. Navab R., Chevet E., Authier F., Di Guglielmo G.M., Bergeron J.J., and Brodt P. Inhibition of endosomal insulin-like growth factor-I processing by cysteine proteinase inhibitors blocks receptor-mediated functions. J. Biol. Chem. 276 (2001) 13644-13649
22. Girnita L., Wang M., Xie Y., Nilsson G., Dricu A., Wejde J., and Larsson O. Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications. Anticancer Drug Des. 15 (2000) 67-72
23. Vasilcanu D., Girnita A., Girnita L., Vasilcanu R., Axelson M., and Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 23 (2004) 7854-7862
24. Larsson O., Girnita A., and Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92 (2005) 2097-2101
25. Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., and Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 64 (2004) 236-242
26. Menu E., Jernberg-Wiklund H., Stromberg T., De Raeve H., Girnita L., Larsson O., Axelson M., Asosingh K., Nilsson K., Van Camp B., and Vanderkerken K. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107 (2006) 655-660
27. Stromberg T., Ekman S., Girnita L., Dimberg L.Y., Larsson O., Axelson M., Lennartsson J., Hellman U., Carlson K., Osterborg A., Vanderkerken K., Nilsson K., and Jernberg-Wiklund H. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107 (2006) 669-678
28. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60 (2000) 3689-3695
29. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
30. Buchardt O., Jensen R.B., Hansen H.F., Nielsen P.E., Andersen D., and Chinoin I. Thermal chemistry of podophyllotoxin in ethanol and a comparison of the cytostatic activity of the thermolysis products. J. Pharm. Sci. 75 (1986) 1076-1080
31. Renwick P.J., Reeves B.R., Dal Cin P., Fletcher C.D., Kempski H., Sciot R., Kazmierczak B., Jani K., Sonobe H., and Knight J.C. Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp11.2, with implications for the histologic sub-classification of synovial sarcoma. Cytogenet. Cell Genet. 70 (1995) 58-63
32. Xie Y., Tornkvist M., Aalto Y., Nilsson G., Girnita L., Nagy B., Knuutila S., and Larsson O. Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 22 (2003) 7628-7631
33. Rubini M., Hongo A., D'Ambrosio C., and Baserga R. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res. 230 (1997) 284-292